高级检索
当前位置: 首页 > 详情页

Correction to: Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study.

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Endocrinology, Peking University People’s Hospital, Beijing, China [2]PegBio Co., Ltd, Suzhou, China [3]Department of Endocrinology, The Third Xiangya Hospital of Central South University, Changsha, China [4]Department of Endocrinology, Nanjing First Hospital, Nanjing, China [5]The Third Endocrinology Department, Cangzhou Central Hospital, Cangzhou, China [6]Department of Endocrinology, Beijing Pinggu Hospital, Beijing, China [7]Department of Endocrinology, Tianjin People’s Hospital, Tianjin, China [8]Department of Endocrinology, The Second Hospital of Jilin University, Changchun, China [9]Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan, China [10]Department of Endocrinology and Diabetes, Chenzhou No 1 People’s Hospital, Chenzhou, China [11]Department of Endocrinology, Zhongda Hospital Southeast University, Nanjing, China [12]Department of Endocrinology, Jinan Central Hospital, Jinan, China [13]Department of Endocrinology, Luoyang Central Hospital, Luoyang, China [14]Department of Endocrinology, Yuncheng Central Hospital, Yuncheng, China [15]Department of Endocrinology, The First Affiliated Hospital of Henan University of Science and Technology, Henan, China [16]Department of Endocrinology, Qingdao Central Hospital, Qingdao, China [17]Department of Endocrinology, Beijing Union Medical College Hospital, Beijing, China [18]Department of Endocrinology, The First People’s Hospital of Changzhou, Changzhou, China [19]Department of Endocrinology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China [20]Department of Endocrinology, Xuzhou Central Hospital, Xuzhou, China [21]Department of Endocrinology, The First People’s Hospital, Changde, China [22]Department of Endocrinology, Guangzhou Red Cross Hospital, Guangzhou, China [23]Department of Endocrinology, Xiangya Hospital Central South University, Changsha, China [24]Department of Endocrinology, Guangzhou Panyu Central Hospital, Guangzhou, China [25]Department of Endocrinology, Anhui Provincial Hospital, Hefei, China [26]Department of Endocrinology, Shandong Provincial Hospital, Jinan, China [27]Department of Endocrinology, The Affiliated Hospital of Qingdao University, Qingdao, China [28]Department of Endocrinology, West China Hospital Sichuan University, Sichuan, China [29]Department of Endocrinology, Beijing Tongren Hospital, CMU, Beijing, China [30]Department of Endocrinology, The First Affiliated Hospital of Zhengzhou University, Henan, China [31]Department of Endocrinology, Affiliated Hospital & Clinical Medical College of Chengdu University, Chengdu, China [32]Department of Endocrinology, Suzhou Municipal Hospital, Suzhou, China
出处:
ISSN:

摘要:
The following sentence in the Discussion was inappropriately changed to a definite statement during editing: ‘Considering the mechanism of action of PB-119, which is similar to exenatide QW, PB-119 also showed superior efficacy compared with available OADs.’

语种:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 1 区 医学
小类 | 1 区 内分泌学与代谢
最新[2023]版:
大类 | 1 区 医学
小类 | 1 区 内分泌学与代谢
第一作者:
第一作者机构: [1]Department of Endocrinology, Peking University People’s Hospital, Beijing, China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:21169 今日访问量:0 总访问量:1219 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)